Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the safety and pharmacokinetics following a single oral dose of MBX-400.


Clinical Trial Description

Cytomegalovirus (CMV; herpesvirus 5), a member of the betaherpesvirus subgroup, occurs as a benign infection in the majority of humans, with a 90% prevalence in the adult population1. However, CMV infection continues to be a major cause of morbidity and mortality in immunosuppressed patients, particularly recipients of solid organ or bone marrow transplants. CMV is also known for its association with severe blinding retinitis, pneumonia and gastrointestinal inflammation in AIDS patients. However, with the successful introduction of HAART (highly active anti-retroviral therapy), the problem of CMV infection in AIDS patients has decreased substantially. CMV remains the most important cause of congenital viral infection in the United States, and CMV infection of neonates is associated with deafness, mental retardation and mortality. In addition, CMV is a suspected pathogenic agent in cardiovascular disease and can persist in large-vessel endothelial cells and infect all cell types involved in cardiovascular lesions. CMV has been implicated in the restenosis of diseased coronary arteries following angioplasty and has been associated with myocarditis. In severely immunocompromised patients with CMV infection, prolonged antiviral therapy is often necessary, which increases the risk of resistant viruses. Currently available therapy has limitations that preclude their long-term use including toxicity, poor oral bioavailability and the development of drug-resistant strains. MBX-400 is a nucleoside analog that is structurally related to ganciclovir and acyclovir and is being developed for the possible use in the prevention and/or treatment of CMV. MBX-400, has been shown to be a potent inhibitor of viral DNA synthesis and therefore may be useful in treating and/or preventing CMV infection. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01433835
Study type Interventional
Source Microbiotix, Inc.
Contact
Status Completed
Phase Phase 1
Start date September 2011
Completion date September 2012

See also
  Status Clinical Trial Phase
Completed NCT03267732 - A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518) Phase 1
Completed NCT05040113 - A Study On Human Mass Balance And Biotransformation Phase 1
Completed NCT04029090 - A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects Phase 1
Completed NCT04586985 - Safety, Tolerability and Pharmacokinetics of FTX-6058 Phase 1
Completed NCT04481789 - Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study) Phase 1
Completed NCT06107205 - Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects Phase 1
Completed NCT04629131 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Healthy Adults Phase 1
Recruiting NCT06063291 - Single Ascending Oral Dose Phase 1 Study of ID110521156 in Healthy Adult Subjects Phase 1
Completed NCT04203862 - A Study of NPC-22 in Healthy Adult Males Phase 1
Recruiting NCT05641181 - A Trial of CRB4101 in Healthy Subjects Phase 1
Completed NCT04521192 - Bioequivalence of Fluzoparib(SHR3162) Study on Healthy Chinese Adult Subjects Phase 1
Completed NCT04400123 - A Bioequivalence Study of Famitinib Malate on Healthy Chinese Volunteers Phase 1
Completed NCT04811469 - Safety, Tolerability and Pharmacokinetics of CBP-174 in Healthy Adults Phase 1
Completed NCT04291846 - A Food Effect Study of SHR1459 on Healthy Chinese Adult Subjects Phase 1
Completed NCT01364441 - Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects Phase 1
Completed NCT02691702 - Multiple Dose Study Of BIIB118 (PF-05251749) In Healthy Volunteers Phase 1
Recruiting NCT05334043 - Pharmacokinetics and Bioavailability of Curcumin UP 30 Capsules in Healthy Adult Subjects Phase 1
Completed NCT04493281 - Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects Phase 1
Completed NCT01376063 - Study to Investigate the Interaction Between FG-4592 and Rosiglitazone in Healthy Adult Subjects Phase 1
Completed NCT04481750 - Study of Oral Edaravone in Healthy Adult Males Phase 1